 |
The Journal of Neuroscience, December 3, 2003, 23(35):11136-11141
Previous Article | Next Article 
Cellular/Molecular
Cannabinoid CB2 Receptors and Fatty Acid Amide Hydrolase Are Selectively Overexpressed in Neuritic Plaque-Associated Glia in Alzheimer's Disease Brains
Cristina Benito,1 *
Estefanía Núñez,1 *
Rosa M. Tolón,1
Erica J. Carrier,2
Alberto Rábano,1
Cecilia J. Hillard,2 and
Julián Romero1
1Laboratorio de Apoyo a la Investigación, Fundación Hospital Alcorcón, 28922 Alcorcón, Madrid, Spain, and 2Department of Pharmacology and Toxicology, Medical College of Wisconsin, Milwaukee, Wisconsin 53226
The endocannabinoid system is still poorly understood. Recently, the basic elements that constitute it, i.e., membrane receptors, endogenous ligands, and mechanisms for termination of the signaling process, have been partially characterized. There is a considerable lack of information, however, concerning the distribution, concentration, and function of those components in the human body, particularly during pathological events. We have studied the status of some of the components of the endocannabinoid system, fatty acid amide hydrolase and cannabinoid CB1 and CB2 receptors, in postmortem brains from patients with Alzheimer's disease. Using specific polyclonal antibodies, we have performed immunohistochemical analysis in hippocampus and entorhinal cortex sections from brains of Alzheimer's disease patients. Our results show that both fatty acid amide hydrolase and cannabinoid CB2 receptors are abundantly and selectively expressed in neuritic plaque-associated astrocytes and microglia, respectively, whereas the expression of CB1 receptors remains unchanged. In addition, the hydrolase activity seems to be elevated in the plaques and surrounding areas. Thus, some elements of the endocannabinoid system may be postulated as possible modulators of the inflammatory response associated with this neurodegenerative process and as possible targets for new therapeutic approaches.
Key words: Alzheimer; astrocyte; astroglia; cannabinoids; immunoreactivity; microglia; neuropathology
Received July 18, 2003;
revised September 15, 2003;
accepted September 16, 2003.
This article has been cited by other articles:

|
 |

|
 |
 
M. Duncan, A. Mouihate, K. Mackie, C. M. Keenan, N. E. Buckley, J. S. Davison, K. D. Patel, Q. J. Pittman, and K. A. Sharkey
Cannabinoid CB2 receptors in the enteric nervous system modulate gastrointestinal contractility in lipopolysaccharide-treated rats
Am J Physiol Gastrointest Liver Physiol,
July 1, 2008;
295(1):
G78 - G87.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. R. Pazos, R. M. Tolon, C. Benito, C. F. Rodriguez, J. J. Gorgojo, M. Nevado, M. Alvarez, F. Arias, F. Almodovar, M. T. P. Fernandez, et al.
Cannabinoid CB1 Receptors Are Expressed by Parietal Cells of the Human Gastric Mucosa
J. Histochem. Cytochem.,
May 1, 2008;
56(5):
511 - 516.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
G. Esposito, T. Iuvone, C. Savani, C. Scuderi, D. De Filippis, M. Papa, V. Di Marzo, and L. Steardo
Opposing Control of Cannabinoid Receptor Stimulation on Amyloid-beta-Induced Reactive Gliosis: In Vitro and in Vivo Evidence
J. Pharmacol. Exp. Ther.,
September 1, 2007;
322(3):
1144 - 1152.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
C. Benito, J. P. Romero, R. M. Tolon, D. Clemente, F. Docagne, C. J. Hillard, C. Guaza, and J. Romero
Cannabinoid CB1 and CB2 Receptors and Fatty Acid Amide Hydrolase Are Specific Markers of Plaque Cell Subtypes in Human Multiple Sclerosis
J. Neurosci.,
February 28, 2007;
27(9):
2396 - 2402.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
P. Pacher, S. Batkai, and G. Kunos
The Endocannabinoid System as an Emerging Target of Pharmacotherapy
Pharmacol. Rev.,
September 1, 2006;
58(3):
389 - 462.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
A. Carracedo, M. Gironella, M. Lorente, S. Garcia, M. Guzman, G. Velasco, and J. L. Iovanna
Cannabinoids Induce Apoptosis of Pancreatic Tumor Cells via Endoplasmic Reticulum Stress-Related Genes.
Cancer Res.,
July 1, 2006;
66(13):
6748 - 6755.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
C. C. Felder, A. K. Dickason-Chesterfield, and S. A. Moore
Cannabinoids Biology: The Search for New Therapeutic Targets
Mol. Interv.,
June 1, 2006;
6(3):
149 - 161.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
G. A. Cabral and F. Marciano-Cabral
Cannabinoid receptors in microglia of the central nervous system: immune functional relevance
J. Leukoc. Biol.,
December 1, 2005;
78(6):
1192 - 1197.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. D. Van Sickle, M. Duncan, P. J. Kingsley, A. Mouihate, P. Urbani, K. Mackie, N. Stella, A. Makriyannis, D. Piomelli, J. S. Davison, et al.
Identification and Functional Characterization of Brainstem Cannabinoid CB2 Receptors
Science,
October 14, 2005;
310(5746):
329 - 332.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
J. L. Shoemaker, B. K. Joseph, M. B. Ruckle, P. R. Mayeux, and P. L. Prather
The Endocannabinoid Noladin Ether Acts as a Full Agonist at Human CB2 Cannabinoid Receptors
J. Pharmacol. Exp. Ther.,
August 1, 2005;
314(2):
868 - 875.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
C. Benito, W.-K. Kim, I. Chavarria, C. J. Hillard, K. Mackie, R. M. Tolon, K. Williams, and J. Romero
A Glial Endogenous Cannabinoid System Is Upregulated in the Brains of Macaques with Simian Immunodeficiency Virus-Induced Encephalitis
J. Neurosci.,
March 9, 2005;
25(10):
2530 - 2536.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
B. G. Ramirez, C. Blazquez, T. G. del Pulgar, M. Guzman, and M. L. de Ceballos
Prevention of Alzheimer's Disease Pathology by Cannabinoids: Neuroprotection Mediated by Blockade of Microglial Activation
J. Neurosci.,
February 23, 2005;
25(8):
1904 - 1913.
[Abstract]
[Full Text]
[PDF]
|
 |
|
|